Physician profile
David D Sova
NPI 1952359895
$1,691.68
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $383 · 2021: $630 · 2022: $69.34 · 2023: $52.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.65 | 2019-2021 | |
| Novo Nordisk INC | $298.37 | 2019-2023 | Saxenda |
| Pfizer INC. | $255.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.48 | 2020-2023 | Farxiga |
| Indivior INC. | $70.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $43.71 | 2020-2021 | |
| Astellas Pharma US INC | $42.67 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $42.63 | 2021 | |
| Lilly USA, LLC | $39.80 | 2019 | |
| Allergan, INC. | $28.63 | 2020 | |
| Antares Pharma, INC. | $27.56 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.78 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.64 | 2021 | |
| Eisai INC. | $24.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.50 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.39 | 2023 | Unithroid |
| Orexo US, INC. | $21.38 | 2019 | |
| Glaxosmithkline, LLC. | $20.52 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.49 | 2019 | |
| Shire North American Group INC | $17.85 | 2019 | |
| Mylan Specialty L.P. | $17.50 | 2019 | |
| Bardy Diagnostics, INC. | $14.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.41 | 2021 | |
| Gilead Sciences, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.